Zhitong Finance App News, Junshi Biotech (01877.HK) issued an announcement. Recently, Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the “Company”) received a “Notice of Acceptance” approved and issued by the State Drug Administration. Treprilimab (trade name: Tuoyi®, product code: JS001) combined with platinum-containing chemotherapy during perioperative treatment, followed by this single drug as an adjuvant treatment for adults who can remove stage II-III non-small cell lung cancer (hereinafter referred to as “NSCLC”) Reasonably, this application is suitable Symptoms expanded from adult patients with resectable stage IIIA-IIIB non-small cell lung cancer to adult patients with resectable stage II-III non-small cell lung cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.